Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TD52 是 PP2A (CIP2A) 癌性抑制剂的口服活性抑制剂。 TD52 是厄洛替尼衍生物,通过干扰 Elk1 与 CIP2A 启动子的结合间接降低了 CIP2A。 在相同实验条件下,摩尔浓度相同的化合物盐形式与游离态具有相同的生物活性,但盐形式 TD52 dihydrochloride 的水溶性和稳定性通常比游离态更好。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 888 | 5日内发货 | ||
100 mg | ¥ 7,940 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 858 | 6-8周 |
TD52 的其他形式现货产品:
产品描述 | TD52 is an orally active inhibitor of cancerous inhibitor of PP2A (CIP2A). TD52 is an Erlotinib derivative and indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. |
体外活性 | TD52 (5 μM; 24 hours) significantly increases the phosphatase activity of PP2A in TNBC cells. TD52 (5 μM; 48 hours) has no obvious effects on other common RTKs, such as IGFR, PDGFR and VEGFR2. TD52 (2-10 μM; 48 hours) shows anti-proliferative ability and induces differential apoptotic effects in these cell lines. TD52 (5 μM; 48 hours) has minimal effects on p-EGFR or EGFR expression but downregulated CIP2A expression. TD52 (2.5, 5, 7.5 μM; 48 hours) time-dependently induces apoptosis accompanied with downregulating CIP2A and p-Akt[1]. |
体内活性 | In female NCr athymic nude mice, TD52 (10 mg/kg/day; oral gavage) significantly inhibited MDA-MB-468 xenograft tumour size and tumour weight and decreased the protein expressions of CIP2A and p-Akt in the three MDA-MB-468 xenograft tumours.[1]. |
分子量 | 360.41 |
分子式 | C24H16N4 |
CAS No. | 1798328-24-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95 mg/mL (263.59 mM), sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7746 mL | 13.8731 mL | 27.7462 mL | 69.3654 mL |
5 mM | 0.5549 mL | 2.7746 mL | 5.5492 mL | 13.8731 mL | |
10 mM | 0.2775 mL | 1.3873 mL | 2.7746 mL | 6.9365 mL | |
20 mM | 0.1387 mL | 0.6937 mL | 1.3873 mL | 3.4683 mL | |
50 mM | 0.0555 mL | 0.2775 mL | 0.5549 mL | 1.3873 mL | |
100 mM | 0.0277 mL | 0.1387 mL | 0.2775 mL | 0.6937 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TD52 1798328-24-1 Apoptosis Cytoskeletal Signaling Metabolism PI3K/Akt/mTOR signaling Akt Phosphatase breast triple-negative inhibit HCC-1937 orally Erlotinib CIP2A Protein kinase B p-Akt p-EGFR TD 52 PKB Elk1 PP2A TD-52 Inhibitor cancer TNBC inhibitor